Back to Search Start Over

Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change.

Authors :
Young, Carolyn A
Chaouch, Amina
Mcdermott, Christopher J
Al-Chalabi, Ammar
Chhetri, Suresh K
Talbot, Kevin
Malaspina, Andrea
Mills, Roger
Tennant, Alan
Source :
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. May2024, Vol. 25 Issue 3/4, p400-409. 10p.
Publication Year :
2024

Abstract

The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score is a widely used measure of functional status in Amyotrophic Lateral Sclerosis/Motor Neuron Disease (ALS), but recent evidence has raised doubts about its validity. The objective was to examine the measurement properties of the ALSFRS-R, aiming to produce valid measurement from all 12 scale items. Longitudinal ALSFRS-R data were collected between 2013-2020 from 1120 people with ALS recruited from 35 centers, together with other scales in the Trajectories of Outcomes in Neurological Conditions-ALS (TONiC-ALS) study. The ALSFRS-R was analyzed by confirmatory factor analysis (CFA), Rasch Analysis (RA) and Mokken scaling. No definite factor structure of the ALSFRS-R was confirmed by CFA. RA revealed the raw score total to be invalid even at the ordinal level because of multidimensionality; valid interval level subscale measures could be found for the Bulbar, Fine-Motor and Gross-Motor domains but the Respiratory domain was only valid at an ordinal level. All four domains resolved into a single valid, interval level measure by using a bifactor RA. The smallest detectable difference was 10.4% of the range of the interval scale. A total ALSFRS-R ordinal raw score can lead to inferential bias in clinical trial results due to its non-linear nature. On the interval level transformation, more than 5 points difference is required before a statistically significant detectable difference can be observed. Transformation to interval level data should be mandatory in clinical trials. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
21678421
Volume :
25
Issue :
3/4
Database :
Academic Search Index
Journal :
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
Publication Type :
Academic Journal
Accession number :
176695494
Full Text :
https://doi.org/10.1080/21678421.2024.2322539